Company Overview of LiRIS Biomedical, Inc.
LiRIS Biomedical, Inc. operates as a pharmaceutical company. The company develops a portfolio of therapeutics to provide controlled-release of drugs directly to target tissues (bladders) to treat bladder diseases. It also offers LiRIS for the treatment of interstitial cystitis. The company was founded in 2008 and is based in Lexington, Massachusetts.
99 Hayden Avenue
Lexington, MA 02421
Founded in 2008
Key Executives for LiRIS Biomedical, Inc.
Chief Executive Officer, President and Director
Co-Founder, Scientific Advisor and Director
Chief Business Officer and Senior Vice President
Compensation as of Fiscal Year 2014.
LiRIS Biomedical, Inc. Key Developments
Taris Biomedical Inc Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015
Mar 17 15
Taris Biomedical Inc Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 . Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.
LiRIS Biomedical, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:30 PM
Feb 26 15
LiRIS Biomedical, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.
TARIS BioMedical Enters Research Collaboration with AstraZeneca for Improved Bladder Cancer Treatments
Oct 16 13
TARIS Biomedical announced that it has entered into a research collaboration with AstraZeneca to evaluate novel treatments for bladder cancer. Under the terms of the agreement, the companies will work together to evaluate multiple novel cancer therapeutics by employing the TARIS(R) proprietary bladder delivery platform in combination with targeted cancer therapeutics from AstraZeneca. The TARIS(R) delivery platform is a soft, flexible system deployed into and retrieved from the bladder using standard urological office procedures. It is designed to provide continuous local delivery to the bladder for days to weeks, depending on the therapeutic application. Furthermore, AstraZeneca has an exclusive option to take a license to the products resulting from the collaboration. This could combine the ability to target both the right tissue - the tumour, with the right genetically targeted therapy and therefore represent a step change in the treatment of this disease.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries